The market for contract manufacturing organisations (CMOs) will be worth US$33.7 billion (Euros 22.4 billion) by 2014 according to the latest Business Monitor International (BMI) report The CMO Market Outlook: Emerging Markets, Key Players and Future Trends published in October 2009, which says developing biologicals/biosimilars capabilities is a key imperative for growth.
- Home
-
Generics
News
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
Research
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
- Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
- Impact of e-bidding procurement on generic omeprazole injection prices in Thailand
- Trajectories of prices in generic drug markets
-
Biosimilars
News
- EC approval of natalizumab, aflibercept and tocilizumab biosimilars
- EMA recommends approval of first ustekinumab biosimilar Uzpruvo
- FDA approves first interchangeable ustekinumab biosimilar Wezlana
- Alvotech biosimilars: FDA ustekinumab application rejection; adalimumab interchangeability designation re-submission
Research
- Switches between biosimilars and their reference products
- Latin America's biosimilars market: regulatory, institutional, and technological aspects
- Impact of trastuzumab biosimilars use in metastatic HER2-positive breast cancer
- Biosimilar anti-VEGF: transforming retina treatment economics in South Asia
- MORE EDITORIAL SECTIONS
- Search
Post your comment